Tags

Type your tag names separated by a space and hit enter

Nonalcoholic fatty liver disease.
Ann Epidemiol. 2007 Nov; 17(11):863-9.AE

Abstract

Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis not associated with a significant intake of ethanol. Insulin resistance is central to the pathogenesis of NAFLD; thus obesity, diabetes, and the metabolic syndrome are frequently associated with the disease. Consequently, as these metabolic conditions emerge as major health problems in Western society, it is now recognized that NAFLD is the most common chronic liver condition in the Western world. NAFLD is generally asymptomatic, although a minority of patients may present with evidence of progressive liver injury with complications of cirrhosis, liver failure, and hepatocellular carcinoma. Despite being common and potentially serious, relatively little is known about the natural history or prognostic significance of NAFLD. Although diabetes, obesity, and age are recognized risk factors for advanced liver disease, other significant factors leading to progressive liver injury remain to be identified. The treatment of NAFLD focuses upon modifying metabolic risk factors. Insulin-sensitizing and hepatoprotective drugs have been subjected to study trials, but as yet, no agent has conclusively been demonstrated to prevent disease progression. Management is further complicated by the inability to predict which patients will develop liver-related morbidity and thus benefit from treatment.

Authors+Show Affiliations

School of Medicine and Pharmacology, The University of Western Australia, Fremantle Hospital Campus, Australia.No affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17728149

Citation

Adams, Leon A., and Keith D. Lindor. "Nonalcoholic Fatty Liver Disease." Annals of Epidemiology, vol. 17, no. 11, 2007, pp. 863-9.
Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17(11):863-9.
Adams, L. A., & Lindor, K. D. (2007). Nonalcoholic fatty liver disease. Annals of Epidemiology, 17(11), 863-9.
Adams LA, Lindor KD. Nonalcoholic Fatty Liver Disease. Ann Epidemiol. 2007;17(11):863-9. PubMed PMID: 17728149.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nonalcoholic fatty liver disease. AU - Adams,Leon A, AU - Lindor,Keith D, Y1 - 2007/08/28/ PY - 2007/04/09/received PY - 2007/05/01/accepted PY - 2007/8/31/pubmed PY - 2007/12/12/medline PY - 2007/8/31/entrez SP - 863 EP - 9 JF - Annals of epidemiology JO - Ann Epidemiol VL - 17 IS - 11 N2 - Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis not associated with a significant intake of ethanol. Insulin resistance is central to the pathogenesis of NAFLD; thus obesity, diabetes, and the metabolic syndrome are frequently associated with the disease. Consequently, as these metabolic conditions emerge as major health problems in Western society, it is now recognized that NAFLD is the most common chronic liver condition in the Western world. NAFLD is generally asymptomatic, although a minority of patients may present with evidence of progressive liver injury with complications of cirrhosis, liver failure, and hepatocellular carcinoma. Despite being common and potentially serious, relatively little is known about the natural history or prognostic significance of NAFLD. Although diabetes, obesity, and age are recognized risk factors for advanced liver disease, other significant factors leading to progressive liver injury remain to be identified. The treatment of NAFLD focuses upon modifying metabolic risk factors. Insulin-sensitizing and hepatoprotective drugs have been subjected to study trials, but as yet, no agent has conclusively been demonstrated to prevent disease progression. Management is further complicated by the inability to predict which patients will develop liver-related morbidity and thus benefit from treatment. SN - 1047-2797 UR - https://www.unboundmedicine.com/medline/citation/17728149/Nonalcoholic_fatty_liver_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1047-2797(07)00217-7 DB - PRIME DP - Unbound Medicine ER -